Introduction
Stem cells are undifferentiated cells that proliferate and have the capacity of both self-renewal and differentiation to one or more types of specialized cells [1] . Recent findings suggest that exogenous stem cells derived from embryonic and adult tissues could be used to regenerate injured or diseased organs, including the lung [2] . The tissues which have observed stem or progenitor activity that can be used strongly in cell-based therapies is bone marrow. The bone marrow contains several hematopoietic stem cells, which could be differentiated into many types such as mature blood cells and mesenchymal stem cells (MSCs), which can be differentiated into bone, fat, cartilage, and other mesenchymal tissues [3] . Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease that leads to significant pulmonary and extrapulmonary risks that may contribute toward morbidity in individual patients. This disease is a common cause of mortality and morbidity worldwide [4] .
When the epithelium is injured, repair starts immediately. At the edge of the wound, dedifferentiation and migration of the unaffected epithelial cells are initiated immediately to cover the injured area and create several proinflammatory cytokines, causing attraction of proteins and cells needed for restoration of the extracellular matrix, which is essential for wound repair. The human lung consists of different trophic units, each lined by specialized types of airway epithelium. The lung can repair itself when injury is detected by the molecular events that can transfer the stem and progenitor cells toward the trophic units [4] .
Patients and methods
This study was carried out on 30 patients with COPD from May 2014 to May 2016. All patients were recruited from the Chest Department, Faculty of Medicine, Tanta University Hospitals. The study was approved by the ethical committee of the faculty of medicine Tanta University.
The participants of the study were divided into three groups:
Group I: 10 patients (seven men and three women) serving as a control group received COPD medication alone according to the Global Initiative for Chronic Obstructive Lung Disease guidelines including inhaled corticosteroids and a long-acting B2 agonist. Group II: 10 patients (seven men and three women) received COPD medication plus stem cell infusion. Group III: 10 patients (six men and four women) received COPD medication plus stem cell inhalation.
Written informed consents were signed by all COPD patients before they were recruited into the study. Patients with forced expiratory volume in 1 s (FEV 1 ) less than 50%, chest or heart disease, malignant tumors, pregnant or lactating patients, and patients with a leukocyte count less than 4000/μl, a platelet count less than 100 000/μl, and hemoglobin less than 10 g/ dl were excluded from this study.
Patient preparation
Full assessment of history and a thorough clinical examination were performed, along with complete laboratory investigations (complete blood count, blood glucose level, kidney function tests, liver function tests, hepatitis B virus antigens, hepatitis C virus antibodies, and HIV antibodies, arterial blood gases). Abdominal ultrasonography and plain chest radiographs, posteroanterior and lateral views, pulmonary function tests by spirometry, and assessment of quality of life by the clinical chronic obstructive pulmonary disease questionnaire (CCQ) were also performed.
Methodology

Stimulation with granulocyte colony-stimulating factor
All COPD patients received granulocyte colonystimulating factor (GeneLeukim Injection; China) by a subcutaneous injection for 3-5 successive days before bone marrow aspiration to stimulate the mobilization of stem cells.
Bone marrow aspiration
Bone marrow of 100-120 ml was collected under local or general anesthesia in heparinized tubes using the bone marrow biopsy needle using a completely aseptic technique.
Isolation of human bone marrow mononuclear cells
The bone marrow aspirate was diluted using clinical buffer (cat. no #700-25, Clini MACS PBS/EDTA; Miltenyi Biotec Company, Bergisch Gladbach, Germany) and then filtered by a bone marrow filter (PALL Medical Filter, UK-pore size 100 μm). The filtered cell suspension was layered slowly over Ficoll-Paque (GE Electric, Pharmacia, USA) in a conical tube and centrifuged for 20 min at 20°C at 2000 rpm with brake off. The mononuclear cell layer (monocytes, thrombocytes, and lymphocytes) was transferred to a sterile tube and the cells were washed three times by clinical buffer; then, the pellet of isolated cells was suspended in 500 μl of clinical buffer [5] .
Stem cell infusion
The separated bone marrow mononuclear cell pool solution including mobilized stem cells was injected with saline into a peripheral vein using a drip infusion pump.
Stem cell inhalation
The prepared bone marrow mononuclear cell pool solution was inhaled through a nebulizer.
Assessment guidelines
The overall clinical COPD scores of the domains and the control score were calculated by dividing the sum of the scores by the number of questions. Thus, the overall clinical COPD score for each of the three domains as well as the control score vary between 0 (very good) and 6 (extremely poor) (6).
After 6, 12, and 24 months, all patients were followed up for the following:
(1) Pulmonary function tests using spirometry.
(2) Quality-of-life questionnaire using the CCQ.
CCQ is used to determine the symptoms and functional state of patients to quantify the effect of the disease on their daily lives and well-being from the patients' point of view. It includes three domains (symptoms, function, and mental domain) (9).
CCQ is short (10 items) and easy to complete. It takes patients ∼2 min to complete the questionnaire. Patients are instructed to report their experiences during the last week. They respond to the questions on a scale of 7 points from 0=asymptomatic/no limitation to 6=extremely symptomatic/totally limited domain.
Results
There were no statistically significant differences (P>0.05) between the groups studied in the values of forced vital capacity (FVC) (% of predicted), FEV 1 % (actual values), the mean values of peak expiratory flow (PEF) (% of predicted), the mean values of maximal mid-expiratory flow (MMEF) (% of predicted), and the mean values of the quality-of-life score ( Figs. 1 and 2) .
In group I, there were no statistically significant differences (P>0.05) before and after treatment in the mean values of FVC (% of predicted), the mean values of FEV 1 % (actual values), the mean values of PEF (% of predicted), the mean values of MMEF (% of predicted), and the mean values of the quality-of-life score ( Figs. 3 and 4) .
In group II, there were no statistically significant differences (P>0.05) before and after treatment in the mean values of FVC (% of predicted), the mean values of FEV 1 % (actual values), the mean values of PEF (% of predicted), and the mean values of MMEF (% of predicted), whereas there was a significant improvement (P<0.001)in the mean values and SD of quality-of-life score as the scores were 6+1 and 2+1, respectively, before and after treatment ( Figs. 5 and 6 ).
In group III, there were no statistically significant differences before and after treatment in the mean values of FVC (% of predicted), the mean values of FEV 1 % (actual values), the mean values of PEF (% of Figure 1 Data of the patients in the studied groups before treatment. FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow.
Figure 2
Quality of life in the patients of the studied groups before treatment.
Figure 3
Spirometry data in group I before and after treatment. FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow.
Figure 4
Quality of life in group I before and after treatment. predicted), and the mean values of MMEF (% of predicted), whereas there was a significant improvement in the mean values and SD of qualityof-life score as the scores were 6+1 and 1+1, respectively, before and after treatment (P<0.001) ( Figs. 7-9 ).
On comparison of the mean values of percent of change of spirometric data in the studied groups before and after treatment, there were no statistically significant differences in FVC (% of predicted), FEV 1 % (actual values), PEF (% of predicted), and MMEF (% of predicted), whereas the mean values of percent of change of quality-of-life scores in groups I, II, and III after treatment were 2, 4, and 5, respectively. The quality-of-life scores in groups II and III were found to be significantly higher (P<0.001) compared with group I.
Discussion
A significant increase in the quality of life was observed in the present study, which direct the attention of changing the natural process of the disease by inhibiting the progression of the disease and also it was free of significant adverse effects. The results showed an insignificant improvement in the pulmonary functions tests, where FEV 1 and FVC showed an insignificant increase in all patients after 24 months of stem cell treatment, both by infusion and by inhalation, and a significant increase in the quality of life in both the groups of COPD patients treated by stem cell infusion or stem cell inhalation compared with the control group.
The National Agency of Sanitary Surveillance stated that the total blood volume that can be aspirated from the bone marrow should not exceed 9 ml/kg for men and 8 ml/kg for women. In our study, we collected between 150 and 200 ml of blood from every patient [6] .
Our findings were more or less similar to those of a study carried out in May 2008, which was a double- Spirometry data in group II before and after treatment. FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow.
Figure 6
Quality of life in group II before and after treatment.
Figure 7
Spirometry data in group III before and after treatment. FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow.
Figure 8
Quality of life in group III before and after treatment.
Figure 9
Percent of change in the studied groups after treatment. FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; PEF, peak expiratory flow.
blinded placebo control phase II trial of allogeneic MSC infusions utilizing PROCHYMALTM for COPD patients with (FEV 1 /FVC<0.70, 30%≤ FEV 1 ≤70%). This study was based on the premise that the anti-inflammatory actions of MSCs will decrease pulmonary inflammation associated with COPD and improve dyspnea, spirometry parameters of the lung, and quality of life [7] .
The study of Yanagi et al. [8] reported contrasting findings to ours; they transplanted stem cells in two patients with mucopolysaccharidosis, and associated with obstructive airway disease and obstructive sleep apnea. They found an improvement in the pulmonary function tests, the cornea became clear, which is clouded in mucopolysaccharidosis patients, and the patients' heart condition improved.
In contrast to our study finding, Yan et al. [8] reported that infusion of bone marrow-derived MSCs at a later stage of lung injury can in fact be deleterious. This leads to the conclusion that an infusion of bone marrowderived MSCs during an ongoing fibrotic response may augment fibrosis.
From this study, it was concluded that autologous stem cells may potentially be useful for treatment and in the next few years, more research will provide us with major insights into the use of stem and progenitor cells as therapeutic agents in COPD.
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